Edwards Lifesciences Corp (EW) : Partner Fund Management reduced its stake in Edwards Lifesciences Corp by 17.47% during the most recent quarter end. The investment management company now holds a total of 969,007 shares of Edwards Lifesciences Corp which is valued at $110,079,195 after selling 205,091 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Edwards Lifesciences Corp makes up approximately 3.76% of Partner Fund Management’s portfolio.
Other Hedge Funds, Including , Walleye Trading sold out all of its stake in EW during the most recent quarter. The investment firm sold 15,005 shares of EW which is valued $1,704,568. Highlander Capital Management added EW to its portfolio by purchasing 400 company shares during the most recent quarter which is valued at $45,440. Edwards Lifesciences Corp makes up approx 0.05% of Highlander Capital Management’s portfolio.Sandy Spring Bank reduced its stake in EW by selling 200 shares or 38.91% in the most recent quarter. The Hedge Fund company now holds 314 shares of EW which is valued at $35,294.Acrospire Investment Management reduced its stake in EW by selling 300 shares or 42.86% in the most recent quarter. The Hedge Fund company now holds 400 shares of EW which is valued at $44,960. Edwards Lifesciences Corp makes up approx 0.03% of Acrospire Investment Management’s portfolio.Greenleaf Trust reduced its stake in EW by selling 7,347 shares or 9.45% in the most recent quarter. The Hedge Fund company now holds 70,418 shares of EW which is valued at $8,064,269. Edwards Lifesciences Corp makes up approx 0.21% of Greenleaf Trust’s portfolio.
Edwards Lifesciences Corp opened for trading at $115.5 and hit $115.985 on the upside on Thursday, eventually ending the session at $115.87, with a gain of 0.62% or 0.71 points. The heightened volatility saw the trading volume jump to 10,97,907 shares. Company has a market cap of $24,666 M.
On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 115 from a previous price target of $100 .Company shares were Reiterated by Canaccord Genuity on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 140 from a previous price target of $132 .Company shares were Reiterated by Leerink Partners on Jul 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 130 from a previous price target of $125 .
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.